Home » Newsletters » BioWorld Science

BioWorld Science

July 4, 1997

View Archived Issues

Company profile: Axiom Biotechnologies

Company profile: Exponential Biotherapies

Company profile: Matrix Pharmaceutical

Novel antiplatelet agent from Cypress Bioscience

Selective 5-HT1D receptor agonist active in two migraine models

Exocell presents new small-molecule antiglycation agent

Guilford's neuroimmunophilin ligand program

Prostaglandins in early development at Allergan for glaucoma

Icos PDE V inhibitor in phase I trials

Guilford presents prototype presynaptic glutamate blocker

PARS inhibitors under development by Guilford for stroke

Name change for Sheffield approved by shareholders

CCK-B antagonist is not effective in anxiety disorders

Etifoxine compared to buspirone for adjustment disorder with anxiety

Low serum cholesterol levels increase risk of suicide in certain psychiatric disorders

Triangle Pharmaceuticals to acquire Avid Corporation

CRF modulator introduced in Italy

Citicoline improves cognitive impairment in animals and elderly subjects

Cholinesterase inhibition with metrifonate studied in rats

SM-13496 preferentially affects mesocortical dopaminergic system

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....